Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05321264
Other study ID # 2021-29
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2023
Est. completion date November 21, 2023

Study information

Verified date June 2023
Source Universidad de Antioquia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the effect of an educational nursing intervention in adults to promote dengue control and prevention behaviors, in comparison with the usual strategy of a health service provider institution. The intervention uses the Nola Pender Health Promotion Model as a theoretical framework. Findings will be assessed using the nursing outcomes "risk control" and "participation in health care decisions" from the Nursing Outcomes Classification (NOC).


Description:

Annually, there are 390 million cases of dengue, mostly due to the inadequate application of sanitary behaviors in the management and control of the vector, having as background the lack of knowledge of the population in the appropriation and incorporation of sanitary measures in the different environments. In addition to the cognitive and behavioral component, dengue has cultural, political, social and economic causes. The evidence indicates that, from health education, educational interventions have been developed to reduce the disease, but most of them have not been carried out in rural areas following a theoretical framework that guides the intervention that leads to an impact on health promoting behaviors. The use of the NOC results makes it possible to visualize the impact of nursing care and constitute scientific support for the advancement of the nursing discipline.


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date November 21, 2023
Est. primary completion date October 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Adults = 18 years old. - Inhabitant of the rural area. - Participant in health promotion and disease prevention programs. - Initial score less than or equal to 3.5 on the NOC outcomes: risk control and participation in health care decisions. Exclusion Criteria: - People with a score less than or equal to 24 on the cognitive mini mental test. - Incomplete registration of information in databases of a health service provider institution. - People with dengue (dengue with warning signs, and severe dengue). - People who do not have mobile phone availability. - Illiterate people.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Educational nursing intervention
Four weekly individualized intervention sessions, with a duration of 40 minutes.

Locations

Country Name City State
Colombia Yolima Judith Llorente Perez Medellín Antioquia

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Antioquia

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Risk control NOC outcome. Personal actions to understand, prevent, eliminate, or reduce modifiable health threats. It includes indicators such as identifies risk factors, acknowledges ability to change behavior, develops effective risk control strategies, commits to risk control strategies and modifies lifestyle to reduce risk. This outcome will be evaluated by a Likert scale, being 1 the worst score and 5 best score. 2 months
Secondary Participation in health care decisions NOC outcome. Personal involvement in selecting and evaluating health care options to achieve desired outcome. It includes indicators such as identifies health outcome priorities, specifies health outcome preference and identifies barriers to desired outcome achievement. This outcome will be evaluated by a Likert scale, being 1 the worst score and 5 best score. 2 months
See also
  Status Clinical Trial Phase
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1
Recruiting NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A